Transcript The point of view of a candidate country

The Point of View of a
Candidate Country
Dr. Peyman Altan
Ministry of Health of Turkey
November 2009
Lisbon
Outline
• General Overview
• Programmes or projects
• The cooperation with Community Agencies
in the public health sector
• Areas and support to be useful for the
cooperation with Community Agencies
• Strong and weak points working with
Community Agencies
• Conclusion
GAZIANTEP- Zeugma Museum
General Overview
• Turkey has had a strong infrastructure
dealing with communicable diseases since
1900..
• Many standarts on communicable
diseases have already been in place
• Illegal drug usage has been a new and
recent phenomenon for Turkey
• Environment has been a major public
health issue for MOH.
MEDA program1
• Reproductive Health Programme has been
carried out by MOH in 1998-2007 having a
budget of Euro 60.000.
• Besides the completion of programme
activities, “National Reproductive Health
Strategies and Action Plan, 2005-2015”
has been started to be implemented
countrywide.
MEDA program2
• The Establishment of Cancer Screening
and Training Centres Project finalised in
December 2004.
Projects1
• 2004 Accession Partnership framework, the
project of strengthening the Ministry of
Health to Harmonise and Implement
Legislation in the Field of Biocides (Biocidal
products) and Water twinning project has
been carried out.
• The biocidal component has been
conducted between November 2005 and
June 2008 while the water component has
been executed between 17 November 2006
and 30 June 2008.
Projects2
• The Project of Strengthening the
•
Epidemiological Surveillance and Control
of Communicable Disease System
(ESCCDS)-I in Turkey (TR 0403.06) and II
(TR 0503.13) have both successfully
completed.
Market Surveillance Support in the
Selected Fields like medical devices
etc.(TR 0402.02) finalised in May 2008.
Projects3
• The project of Avian Influenza
•
Preparedness and Response (TR 06.AI)
has been still going on.
Under IPA, receiving technical assistance
from EMCDDA, a Prevalence and
Behavioural Study on HIV, Hepatitis B,
Hepatitis C and Tuberculosis among
Intravenous Drug Users in Gaziantep has
been recently finalised.
The cooperation with Community
Agencies in the public health sector
The cooperation with Community
Agencies in the public health sector
•
•
•
•
•
•
The technical assistance is available; EMCDDA and ECDC.
Data periodically sent from MOH; ECDC and EMCDDA.
EPIET trainings.
“Establishment of a National Drugs Monitoring Centre
(Reitox Focal Point) and development and implementation
of a National Drugs Strategy” (TR02-JH-04)--MOH
Contribution to Annual National Drug Control Report
A new project under IPA 2010 Programming, the
“Strengthening the Prevention of Illegal Drug Use in Turkey”
project has been prepared by MOH and has been currently
discussed by EU General Secretariat……
Areas and support to be useful for
the cooperation with CAs
•
•
•
•
•
More technical and financial support to carry out research
activities to determine the illegal drug usage characteristics
in Turkey.
To be in direct contact with EMCDDA to strengthen some of
the activities taken place in the National Drug Control
Programme of Turkey.
To share best practices of Member States through
EMCDDA, ECDC and EEA.
To have an observer status and to attend meetings
organized for Member States having also the right to
comment and contribute.
To be considered appropriate by ECDC for the requests of
Turkey on further EPIET training; Strengthening the
Epidemiological Surveillance and Control of Communicable
Disease System (ESCCDS)-II Project.
Strong and weak points working
with Community Agencies
• Strong points
• Ongoing mutual collaboration
• Mutual trust
• Technical support; the implementation of
new projects, databases in public health…
• Weak points
• Sometimes institutional resistance outside
of MOH, Turkey ESPAD 2008.
Conclusion
•
•
•
•
•
To increase the mutual collaboration and cooperation with
CAs.
To have an observer status and to attend EU meetings and
activities and having the right to comment and contribute.
To have the possibility to access to other EU member data
as commonly used by Member States.
To have a close cooperation with EMCDDA to receive a
technical assistance as well as sharing other country
experiences while carrying out some of National Drug
Control Program Activities.
To become stronger improving the collaboration with
Community Agencies as well as Member States and
closing the gaps.
THANK YOU